Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
about
Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium.Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men.Single-dose pharmacokinetics of ceftriaxone in infants and young children.Efficacy of ceftriaxone in serious bacterial infections.Activities of eight new beta-lactam antibiotics and seven antibiotic combinations against Neisseria meningitidis.Comparative activities of 13 beta-lactam antibioticsCeftriaxone: in vitro studies and clinical evaluationCeftriaxone (Ro 13-9904) therapy of serious infection.Differences in susceptibilities of species of the Bacteroides fragilis group to several beta-lactam antibiotics: indole production as an indicator of resistance.In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeaeCeftriaxone versus povidone iodine in preventing wound infections following biliary surgeryInfluence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalisUse of third-generation cephalosporins. Pseudomonas.Use of third-generation cephalosporins. Enterobacteriaceae.Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life.In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.Once-daily ceftriaxone for skin and soft tissue infections.In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.Efficacy and safety of ceftriaxone in serious pediatric infections.[N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].
P2860
Q34167667-B96EE098-DCAB-4517-AF81-987FE305C770Q35671926-0A9E953A-4098-47EC-98BA-32F1FB2BBEC1Q35672864-ADFD1B64-5B92-493A-BFAC-A60845386E26Q35673633-1BE12DF1-AE02-4ADB-8C82-4FBBDE54684AQ35674264-B59937D8-BA3F-49D6-ADD5-12DAC3A02F9AQ35675331-940F09F3-550C-455D-A77A-79699B45B49AQ35676188-D68D40E5-B541-4EB9-BFA4-F51B8FAC2850Q35712352-D036DE94-C211-464E-B8CB-D2B1477B124BQ35712560-39BE49C7-E1CA-4A1D-93A4-55C7B6F9ECDEQ35718303-2DB37CE2-ADF1-48F9-A9E9-8AEFD0B1C983Q35740391-3CDED881-BA7D-4B8A-99EA-B3B1C7E281A1Q36815860-041D047C-BA43-4675-A098-4CD5E3D20C90Q37269692-3862F909-0876-4467-92C0-41E0D35B0785Q37381368-5A30CBC4-2F97-48E9-954B-99B830758320Q37381380-1B2693F7-B568-400F-8ACA-DD438A5E6CBBQ39835731-B0680119-CF10-4D21-B4D4-51875DF71BA9Q39849664-D48E51A1-0B77-4ADA-8569-B9EB8898A2B7Q39849744-3B3D37FE-271D-4EC6-872E-4F8568CB72F8Q39857062-710D7262-E7BD-4020-A245-C7C2FBCECD28Q41822236-2DE7F46F-CB64-4E73-8481-5BEEA6624935Q41833169-88DD87A6-4BB3-4D5A-A8E0-996CD11CFE12Q44882404-91256B8C-748E-465E-8514-3C85AE3EBF54
P2860
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh
1981年學術文章
@zh-hant
name
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@en
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@nl
type
label
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@en
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@nl
prefLabel
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@en
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@nl
P2860
P356
P1476
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
@en
P2093
P2860
P304
P356
10.1128/AAC.19.3.435
P407
P577
1981-03-01T00:00:00Z